NO174825B - Fremgangsmåte ved påvisning av nukleotidsekvenser, nukleotidsekvens for bruk i denne og diagnostisk sett - Google Patents
Fremgangsmåte ved påvisning av nukleotidsekvenser, nukleotidsekvens for bruk i denne og diagnostisk sett Download PDFInfo
- Publication number
- NO174825B NO174825B NO891012A NO891012A NO174825B NO 174825 B NO174825 B NO 174825B NO 891012 A NO891012 A NO 891012A NO 891012 A NO891012 A NO 891012A NO 174825 B NO174825 B NO 174825B
- Authority
- NO
- Norway
- Prior art keywords
- nucleotide
- primer
- diagnostic
- sequence
- complementary
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 75
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 39
- 239000002773 nucleotide Substances 0.000 claims abstract description 313
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 306
- 230000000295 complement effect Effects 0.000 claims abstract description 100
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 63
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 41
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 41
- 230000003321 amplification Effects 0.000 claims description 108
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 108
- 239000001226 triphosphate Substances 0.000 claims description 75
- 235000011178 triphosphate Nutrition 0.000 claims description 75
- -1 nucleoside triphosphates Chemical class 0.000 claims description 61
- 239000002777 nucleoside Substances 0.000 claims description 60
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 27
- 208000016361 genetic disease Diseases 0.000 claims description 26
- 238000001514 detection method Methods 0.000 claims description 25
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- 238000003786 synthesis reaction Methods 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000000379 polymerizing effect Effects 0.000 claims description 10
- 125000003835 nucleoside group Chemical group 0.000 claims description 7
- 238000006116 polymerization reaction Methods 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000010306 acid treatment Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000013615 primer Substances 0.000 description 333
- 239000000047 product Substances 0.000 description 138
- 108020004414 DNA Proteins 0.000 description 91
- 239000000523 sample Substances 0.000 description 87
- 108091034117 Oligonucleotide Proteins 0.000 description 52
- 230000035772 mutation Effects 0.000 description 43
- 238000003752 polymerase chain reaction Methods 0.000 description 42
- 102000004190 Enzymes Human genes 0.000 description 30
- 108090000790 Enzymes Proteins 0.000 description 30
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 28
- 239000000499 gel Substances 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 15
- 238000001962 electrophoresis Methods 0.000 description 14
- 239000002753 trypsin inhibitor Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 238000012800 visualization Methods 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 239000012985 polymerization agent Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 9
- 108010006785 Taq Polymerase Proteins 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 102000051631 human SERPINA1 Human genes 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229940104302 cytosine Drugs 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 5
- 229960005542 ethidium bromide Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 230000002787 reinforcement Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 101710081722 Antitrypsin Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 208000002903 Thalassemia Diseases 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001687 destabilization Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
- 229960005508 8-azaguanine Drugs 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 241000589500 Thermus aquaticus Species 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012502 diagnostic product Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229940059904 light mineral oil Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101100025420 Arabidopsis thaliana XI-C gene Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034502 Haemoglobin C disease Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 201000006288 alpha thalassemia Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MKZUDFZKTZOCRS-UHFFFAOYSA-N diphosphono hydrogen phosphate;1h-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.OP(O)(=O)OP(O)(=O)OP(O)(O)=O MKZUDFZKTZOCRS-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004876 x-ray fluorescence Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888805692A GB8805692D0 (en) | 1988-03-10 | 1988-03-10 | Method of detecting nucleotide sequences |
| GB888814170A GB8814170D0 (en) | 1988-06-15 | 1988-06-15 | Method of detecting nucleotide sequences |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO891012D0 NO891012D0 (no) | 1989-03-09 |
| NO891012L NO891012L (no) | 1989-09-11 |
| NO174825B true NO174825B (no) | 1994-04-05 |
| NO174825C NO174825C (da) | 1994-07-13 |
Family
ID=26293607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO891012A NO174825B (no) | 1988-03-10 | 1989-03-09 | Fremgangsmåte ved påvisning av nukleotidsekvenser, nukleotidsekvens for bruk i denne og diagnostisk sett |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5595890A (da) |
| EP (1) | EP0332435B2 (da) |
| JP (1) | JP2853864B2 (da) |
| KR (1) | KR970003151B1 (da) |
| CN (1) | CN1034673C (da) |
| AT (1) | ATE75262T1 (da) |
| AU (1) | AU614584B2 (da) |
| BR (1) | BR8901136A (da) |
| CA (1) | CA1323592C (da) |
| DE (1) | DE68901285D1 (da) |
| DK (1) | DK175527B1 (da) |
| ES (1) | ES2039294T5 (da) |
| FI (1) | FI891126A (da) |
| GR (2) | GR3004442T3 (da) |
| HU (1) | HUT52565A (da) |
| IE (1) | IE61148B1 (da) |
| IL (1) | IL89545A (da) |
| MY (1) | MY104957A (da) |
| NO (1) | NO174825B (da) |
| NZ (1) | NZ228266A (da) |
| PL (1) | PL162338B1 (da) |
| PT (1) | PT89980B (da) |
| TN (1) | TNSN89026A1 (da) |
| YU (1) | YU49789A (da) |
| ZW (1) | ZW3388A1 (da) |
Families Citing this family (252)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4038804A1 (de) | 1990-10-09 | 1992-04-16 | Boehringer Mannheim Gmbh | Verfahren zur genus- oder/und spezies-spezifischen detektion von bakterien in einer probenfluessigkeit |
| EP0333465B1 (en) * | 1988-03-18 | 1994-07-13 | Baylor College Of Medicine | Mutation detection by competitive oligonucleotide priming |
| FR2650840B1 (fr) * | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| GB8920097D0 (en) * | 1989-09-06 | 1989-10-18 | Ici Plc | Amplification processes |
| JPH03123500A (ja) * | 1989-10-06 | 1991-05-27 | Canon Inc | 核酸の分別方法 |
| GB9001181D0 (en) * | 1990-01-18 | 1990-03-21 | Imp Cancer Res Tech | Genetic assay |
| IL97222A (en) * | 1990-02-16 | 1995-08-31 | Orion Yhtymae Oy | Method and Responder for Determining Special Changes to Nucleotide |
| US6013431A (en) | 1990-02-16 | 2000-01-11 | Molecular Tool, Inc. | Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators |
| GB9006924D0 (en) * | 1990-03-28 | 1990-05-23 | Imperial College | Prognosis of hepatitis infection |
| US5844108A (en) * | 1990-06-22 | 1998-12-01 | Roche Molecular Systems, Inc. | Primers targeted to NAT2 gene for detection of poor metabolizers of drugs |
| DE69126064T2 (de) * | 1990-06-22 | 1997-08-28 | Hoffmann La Roche | Nachweis von schwachen Metabolisierungsreagentien von Drogen |
| GB9019512D0 (en) * | 1990-09-06 | 1990-10-24 | Ici Plc | Assay method |
| FR2668162B1 (fr) * | 1990-10-17 | 1993-01-22 | Eurobio Lab | Fragments d'adn, procede et coffret de diagnostic pour la detection des porteurs de la mutation delta-f-508 responsable de la mucoviscidose. |
| IE66125B1 (en) * | 1991-01-31 | 1995-12-13 | Zeneca Ltd | Detection method for variant nucleotides |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| ATE190096T1 (de) * | 1991-08-27 | 2000-03-15 | Zeneca Ltd | Verfahren zur charakterisierung genomischer dna |
| US5853989A (en) * | 1991-08-27 | 1998-12-29 | Zeneca Limited | Method of characterisation of genomic DNA |
| DE4129653A1 (de) * | 1991-09-06 | 1993-03-11 | Boehringer Mannheim Gmbh | Verfahren zum nachweis aehnlicher nukleinsaeuren |
| IL103935A0 (en) * | 1991-12-04 | 1993-05-13 | Du Pont | Method for the identification of microorganisms by the utilization of directed and arbitrary dna amplification |
| US5541060A (en) * | 1992-04-22 | 1996-07-30 | Arch Development Corporation | Detection of glucokinase-linked early-onset non-insulin-dependent diabetes mellitus |
| US6180338B1 (en) | 1992-08-04 | 2001-01-30 | Beckman Coulter, Inc. | Method, reagent and kit for the detection and amplification of nucleic acid sequences |
| US6207368B1 (en) | 1992-08-04 | 2001-03-27 | Beckman Coulter, Inc. | Methods and reagents for controlling chain extension and ligation chain reactions |
| WO1994008047A1 (en) * | 1992-09-25 | 1994-04-14 | Abbott Laboratories | Ligase chain reaction method for detecting small mutations |
| US6335184B1 (en) | 1993-07-23 | 2002-01-01 | Bio-Rad Laboratories, Inc. | Linked linear amplification of nucleic acids |
| EP0710296A4 (en) * | 1993-07-23 | 1999-05-26 | Bio Rad Laboratories | LINEAR AMPLIFICATION OF NUCLEIC ACIDS |
| AU1911395A (en) * | 1994-02-04 | 1995-08-21 | Beckman Instruments, Inc. | Method, reagent and kit for the detection and amplification of nucleic acid sequences |
| JP2002503943A (ja) | 1994-08-12 | 2002-02-05 | ミリアド・ジェネティックス・インコーポレイテッド | １７ｑ−連鎖乳癌および卵巣癌感受性遺伝子におけるイン・ビボ突然変異および多形性 |
| ES2154712T5 (es) | 1994-08-12 | 2009-12-14 | The University Of Utah Research Foundation | Metodo para diagnosticar la predisposicion al cancer de mama y de ovarios. |
| FR2737732B1 (fr) * | 1995-08-07 | 1997-10-10 | Ass Francaise Contre La Myopat | Test co-dominant de diagnostic genetique |
| US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
| IL124620A0 (en) | 1995-12-18 | 1998-12-06 | Myriad Genetics Inc | Chromosome 13-linked breast cancer susceptibility gene |
| ATE427993T1 (de) | 1995-12-22 | 2009-04-15 | Univ Utah Res Found | EIN GEN DES ßLANGEN QT SYNDROMSß (LONG QT SYNDROM), WELCHES KVLQT1 KODIERT UND SEINE WECHSELWIRKUNG MIT MINK |
| NO960163D0 (no) * | 1996-01-15 | 1996-01-15 | Thomas Berg | Mutasjonsdeteksjon av bovin |
| US5612473A (en) * | 1996-01-16 | 1997-03-18 | Gull Laboratories | Methods, kits and solutions for preparing sample material for nucleic acid amplification |
| WO1997035033A1 (en) | 1996-03-19 | 1997-09-25 | Molecular Tool, Inc. | Method for determining the nucleotide sequence of a polynucleotide |
| GB9609441D0 (en) * | 1996-05-04 | 1996-07-10 | Zeneca Ltd | Process |
| US6361940B1 (en) | 1996-09-24 | 2002-03-26 | Qiagen Genomics, Inc. | Compositions and methods for enhancing hybridization and priming specificity |
| IL119342A0 (en) * | 1996-10-02 | 1997-01-10 | Yeda Research And Development C | Methods for priming and DNA sequencing |
| US6566101B1 (en) | 1997-06-16 | 2003-05-20 | Anthony P. Shuber | Primer extension methods for detecting nucleic acids |
| US5888778A (en) * | 1997-06-16 | 1999-03-30 | Exact Laboratories, Inc. | High-throughput screening method for identification of genetic mutations or disease-causing microorganisms using segmented primers |
| GB9721240D0 (en) * | 1997-10-08 | 1997-12-03 | Zeneca Ltd | Assay |
| US6794133B1 (en) | 1997-12-11 | 2004-09-21 | The General Hospital Corporation | Broad range PCR amplification techniques |
| WO1999044045A1 (en) * | 1998-02-27 | 1999-09-02 | Massachusetts Institute Of Technology | Single molecule detection with surface-enhanced raman scattering and applications in dna or rna sequencing |
| GB9812768D0 (en) * | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
| US6207379B1 (en) | 1998-09-11 | 2001-03-27 | One Lambda | Method for amplification of DNA |
| KR20010090879A (ko) | 1998-12-08 | 2001-10-19 | 추후제출 | 대장균주 오157:에이치7을 타 균주와 구별하는 다형성유전자좌 |
| US6503718B2 (en) | 1999-01-10 | 2003-01-07 | Exact Sciences Corporation | Methods for detecting mutations using primer extension for detecting disease |
| US6280947B1 (en) | 1999-08-11 | 2001-08-28 | Exact Sciences Corporation | Methods for detecting nucleotide insertion or deletion using primer extension |
| CN1361829A (zh) | 1999-03-18 | 2002-07-31 | 埃克西库恩公司 | 利用特异性lna引物检测基因突变 |
| US20060275782A1 (en) * | 1999-04-20 | 2006-12-07 | Illumina, Inc. | Detection of nucleic acid reactions on bead arrays |
| US20030215821A1 (en) * | 1999-04-20 | 2003-11-20 | Kevin Gunderson | Detection of nucleic acid reactions on bead arrays |
| US20020025519A1 (en) * | 1999-06-17 | 2002-02-28 | David J. Wright | Methods and oligonucleotides for detecting nucleic acid sequence variations |
| EP1061134A3 (en) * | 1999-06-17 | 2003-01-08 | Becton Dickinson and Company | Oligonucleotides for amplification and detection of hemochromatosis genes |
| US20030165913A1 (en) * | 1999-06-17 | 2003-09-04 | Sha-Sha Wang | Methods for detecting nucleic acid sequence variations |
| NZ516278A (en) | 1999-06-22 | 2004-03-26 | Invitrogen Corp | Improved primers and methods for the detection and discrimination of nucleic acids |
| US6830902B1 (en) * | 1999-07-02 | 2004-12-14 | Invitrogen Corporation | Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| EP1072679A3 (en) * | 1999-07-20 | 2002-07-31 | Agilent Technologies, Inc. (a Delaware corporation) | Method of producing nucleic acid molecules with reduced secondary structure |
| DE10038229B4 (de) | 1999-08-24 | 2011-06-09 | LG Electronics Inc., Kangnam-gu | Verfahren und Vorrichtung zur Ratenanpassung in einem Mobilkommunikationssystem |
| US6528066B1 (en) | 1999-09-14 | 2003-03-04 | University Of Iowa Research Foundation | Variant varicella-zoster viruses and methods of use |
| AU2000278349A1 (en) * | 1999-09-28 | 2001-04-30 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the interleukin 13 gene |
| US20030148301A1 (en) * | 1999-12-10 | 2003-08-07 | Toshiya Aono | Method of detecting nucleotide polymorphism |
| WO2003074738A1 (en) * | 2000-01-18 | 2003-09-12 | Quantom Dot Corporation | Oligonucleotide-tagged semiconductor nanocrystals for microarray and fluorescence in situ hybridization |
| US20050214825A1 (en) * | 2000-02-07 | 2005-09-29 | John Stuelpnagel | Multiplex sample analysis on universal arrays |
| US8076063B2 (en) * | 2000-02-07 | 2011-12-13 | Illumina, Inc. | Multiplexed methylation detection methods |
| US7955794B2 (en) | 2000-09-21 | 2011-06-07 | Illumina, Inc. | Multiplex nucleic acid reactions |
| US7582420B2 (en) | 2001-07-12 | 2009-09-01 | Illumina, Inc. | Multiplex nucleic acid reactions |
| US7435541B2 (en) * | 2000-05-23 | 2008-10-14 | Sequenom, Inc. | Restriction enzyme genotyping |
| US7659054B1 (en) * | 2000-05-23 | 2010-02-09 | Nuvelo, Inc. | Methods for genetic analysis of DNA to detect sequence variances |
| WO2002004673A1 (en) * | 2000-07-12 | 2002-01-17 | Bionex, Inc. | Method for detecting sequence variation of nucleic acid |
| JP3638516B2 (ja) * | 2000-09-28 | 2005-04-13 | 株式会社日立製作所 | 核酸検出方法および核酸検出キット |
| US6428964B1 (en) | 2001-03-15 | 2002-08-06 | Exact Sciences Corporation | Method for alteration detection |
| US6986992B2 (en) * | 2001-03-30 | 2006-01-17 | Amersham Biosciences Ab | P450 single nucleotide polymorphism biochip analysis |
| CN1186456C (zh) * | 2001-04-30 | 2005-01-26 | 曹卫 | 通用模板核酸检测方法和试剂盒 |
| US7888324B2 (en) | 2001-08-01 | 2011-02-15 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| WO2003027309A2 (en) | 2001-09-24 | 2003-04-03 | One Lambda | Diagnostic probe detection system |
| US20030165859A1 (en) | 2001-10-23 | 2003-09-04 | Invitrogen Corporation | Primers and methods for the detection and discrimination of nucleic acids |
| WO2003066897A2 (en) * | 2002-02-08 | 2003-08-14 | Evotec Technologies Gmbh | Specific multiplex analysis of nucleic acids |
| AU2003213107A1 (en) | 2002-02-15 | 2003-09-09 | Exact Sciences Corporation | Methods for analysis of molecular events |
| JP3752466B2 (ja) * | 2002-04-24 | 2006-03-08 | 株式会社日立製作所 | 遺伝子検査方法 |
| US7192700B2 (en) | 2002-12-20 | 2007-03-20 | Orchid Cellmark Inc. | Methods and compositions for conducting primer extension and polymorphism detection reactions |
| US7238476B2 (en) | 2002-08-02 | 2007-07-03 | Orchid Cellmark, Inc. | Methods and compositions for genotyping |
| US9394332B2 (en) | 2002-08-29 | 2016-07-19 | Epigenomics Ag | Method for bisulfite treatment |
| US20040121374A1 (en) * | 2002-10-02 | 2004-06-24 | Yoshihide Iwaki | Method for detecting single nucleotide polymorphisms |
| US20040259105A1 (en) * | 2002-10-03 | 2004-12-23 | Jian-Bing Fan | Multiplex nucleic acid analysis using archived or fixed samples |
| JP4425142B2 (ja) * | 2002-11-07 | 2010-03-03 | 洋一 松原 | 遺伝子変異検出法 |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| CA2507189C (en) | 2002-11-27 | 2018-06-12 | Sequenom, Inc. | Fragmentation-based methods and systems for sequence variation detection and discovery |
| ATE373673T1 (de) * | 2003-01-29 | 2007-10-15 | Hoffmann La Roche | Verbessertes verfahren zur behandlung durch bisulfit |
| US20040224336A1 (en) * | 2003-03-11 | 2004-11-11 | Gene Check, Inc. | RecA-assisted specific oligonucleotide extension method for detecting mutations, SNPs and specific sequences |
| KR20070121853A (ko) | 2003-03-31 | 2007-12-27 | 에프. 호프만-라 로슈 아게 | 일본 뇌염 바이러스 혈청군의 구성원을 포함하는, 특정플라비바이러스 검출용 조성물 및 방법 |
| US20040219532A1 (en) * | 2003-04-30 | 2004-11-04 | Sampson Jeffrey R. | Internal references measurements |
| US20050181394A1 (en) * | 2003-06-20 | 2005-08-18 | Illumina, Inc. | Methods and compositions for whole genome amplification and genotyping |
| WO2005003304A2 (en) | 2003-06-20 | 2005-01-13 | Illumina, Inc. | Methods and compositions for whole genome amplification and genotyping |
| US20040259100A1 (en) * | 2003-06-20 | 2004-12-23 | Illumina, Inc. | Methods and compositions for whole genome amplification and genotyping |
| GB0317592D0 (en) | 2003-07-26 | 2003-08-27 | Astrazeneca Ab | Method |
| ES2379553T3 (es) * | 2003-08-29 | 2012-04-27 | Instituto Nacional De Tecnologia Agropecuaria | Plantas de arroz que tienen tolerancia aumentada a herbicidas de imidazolinona |
| WO2005024068A2 (en) | 2003-09-05 | 2005-03-17 | Sequenom, Inc. | Allele-specific sequence variation analysis |
| US7501240B2 (en) | 2003-12-02 | 2009-03-10 | Roche Molecular Systems, Inc. | Method for bisulfite treatment |
| US7129049B2 (en) | 2003-12-22 | 2006-10-31 | Regents Of The University Of Minnesota | Method of detecting equine glycogen storage disease IV |
| US7432082B2 (en) * | 2004-03-22 | 2008-10-07 | Basf Ag | Methods and compositions for analyzing AHASL genes |
| EP2395098B1 (en) | 2004-03-26 | 2015-07-15 | Agena Bioscience, Inc. | Base specific cleavage of methylation-specific amplification products in combination with mass analysis |
| US20050287558A1 (en) | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
| US7939251B2 (en) | 2004-05-06 | 2011-05-10 | Roche Molecular Systems, Inc. | SENP1 as a marker for cancer |
| EP1766068A4 (en) | 2004-06-04 | 2010-03-03 | Genentech Inc | EGFR Mutations |
| US20060029954A1 (en) * | 2004-06-30 | 2006-02-09 | Applera Corporation | Compositions and methods for identifying nucleotides in polynucleotide sequences |
| RU2415566C2 (ru) * | 2004-07-30 | 2011-04-10 | Басф Агрокемикал Продактс Б.В. | Устойчивые к гербицидам растения подсолнечника, полинуклеотиды, кодирующие устойчивые к гербицидам белки большой субъединицы ацетогидроксиацидсинтазы, и способы применения |
| WO2006026654A2 (en) | 2004-08-27 | 2006-03-09 | Exact Sciences Corporation | Method for detecting a recombinant event |
| EP1632578A1 (en) * | 2004-09-03 | 2006-03-08 | Roche Diagnostics GmbH | DNA decontamination method |
| US9109256B2 (en) | 2004-10-27 | 2015-08-18 | Esoterix Genetic Laboratories, Llc | Method for monitoring disease progression or recurrence |
| JP2006129811A (ja) * | 2004-11-08 | 2006-05-25 | Hitachi Ltd | 試料核酸の分析方法、分析装置および分析キット |
| US20060105348A1 (en) * | 2004-11-15 | 2006-05-18 | Lee Jun E | Compositions and methods for the detection and discrimination of nucleic acids |
| US20060275792A1 (en) * | 2004-11-15 | 2006-12-07 | Lee Jun E | Enhancement of nucleic acid amplification using double-stranded DNA binding proteins |
| GB0428255D0 (en) | 2004-12-23 | 2005-01-26 | Health Prot Agency | Detection of nucleic acid mutations |
| ES2692594T1 (es) * | 2005-03-02 | 2018-12-04 | Instituto Nacional De Tecnologia Agropecuaria | Plantas de arroz resistentes a herbicidas, polinucleótidos que codifican proteínas de la subunidad grande de la acetohidroxiácido sintasa resistentes a herbicidas y métodos para su uso |
| GB2424886A (en) | 2005-04-04 | 2006-10-11 | Dxs Ltd | Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations |
| JP2008538501A (ja) | 2005-04-20 | 2008-10-30 | オークランド ユニサービシーズ リミティド | ベシキュリン |
| US9777314B2 (en) | 2005-04-21 | 2017-10-03 | Esoterix Genetic Laboratories, Llc | Analysis of heterogeneous nucleic acid samples |
| TR200709185T2 (tr) * | 2005-07-01 | 2008-02-21 | Basf Aktiengesellschaft | Herbisitlere dayanıklı ayçiçeği bitkileri, herbisitlere dayanıklı asetohidroksiasit sintaz geniş alt ünite proteinlerini kodlayan polinükleotidler ve kullanma metotları |
| GB0514913D0 (en) * | 2005-07-20 | 2005-08-24 | Univ Birmingham | Polymorphism |
| WO2007134014A2 (en) | 2006-05-05 | 2007-11-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of gcgr |
| US7759062B2 (en) | 2006-06-09 | 2010-07-20 | Third Wave Technologies, Inc. | T-structure invasive cleavage assays, consistent nucleic acid dispensing, and low level target nucleic acid detection |
| KR100812259B1 (ko) * | 2006-06-12 | 2008-03-10 | 주식회사 씨젠 | 기지의 서열에 인접한 미지의 ｄｎａ 서열을 증폭하는 방법 |
| EP2377953A1 (en) | 2006-06-23 | 2011-10-19 | Myriad Genetics, Inc. | DPYD gene variants and use thereof |
| MX2009002471A (es) | 2006-09-07 | 2009-03-20 | Astrazeneca Ab | Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora. |
| WO2008070370A2 (en) * | 2006-11-02 | 2008-06-12 | University Of Utah Research Foundation | Oligonucleotides for use in allele-specific pcr |
| UA108733C2 (uk) | 2006-12-12 | 2015-06-10 | Толерантна до гербіциду рослина соняшника | |
| US9938641B2 (en) * | 2006-12-18 | 2018-04-10 | Fluidigm Corporation | Selection of aptamers based on geometry |
| EP2913341A1 (en) | 2006-12-22 | 2015-09-02 | University of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
| US8314220B2 (en) * | 2007-01-26 | 2012-11-20 | Agilent Technologies, Inc. | Methods compositions, and kits for detection of microRNA |
| KR20150090284A (ko) | 2007-03-24 | 2015-08-05 | 젠자임 코포레이션 | 인간 아포리포프로틴 ｂ에 상보적인 안티센스 올리고뉴클레오타이드 투여 |
| US10017827B2 (en) | 2007-04-04 | 2018-07-10 | Nidera S.A. | Herbicide-resistant sunflower plants with multiple herbicide resistant alleles of AHASL1 and methods of use |
| DK2076289T3 (da) | 2007-04-13 | 2015-02-09 | Dana Farber Cancer Inst Inc | Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider |
| CA2686211C (en) | 2007-05-03 | 2018-08-21 | One Lambda Inc. | Methods of screening for binding interaction using sets of microparticles and unique probes |
| WO2008144761A2 (en) | 2007-05-21 | 2008-11-27 | Genentech, Inc. | Methods and compositions for identifying and treating lupus |
| US20100203051A1 (en) | 2007-05-31 | 2010-08-12 | The University Of Queensland | Diagnostic markers for ankylosing spondylitis and uses thereof |
| BRPI0811271A2 (pt) * | 2007-05-31 | 2015-01-20 | Monsanto Technology Llc | Polimorfismos da soja e processos de genotipagem |
| WO2009021054A2 (en) | 2007-08-06 | 2009-02-12 | Orion Genomics Llc | Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene |
| EP2735619A3 (en) | 2007-08-29 | 2014-08-13 | Monsanto Technology LLC | Methods and compositions for breeding for preferred traits associated with Goss' Wilt resistance in plants |
| CA2639416C (en) | 2007-09-11 | 2019-12-31 | F. Hoffmann-La Roche Ag | Diagnostic test for susceptibility to b-raf kinase inhibitors |
| GB2453173A (en) | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| US20120142608A1 (en) | 2007-11-01 | 2012-06-07 | University of Iowa Research Foundation Corporation | Rca locus analysis to assess susceptibility to amd and mpgnii |
| WO2009059199A2 (en) * | 2007-11-02 | 2009-05-07 | Hunch Inc. | Interactive machine learning advice facility |
| WO2009074882A2 (en) * | 2007-11-02 | 2009-06-18 | Luminex Molecular Diagnostics, Inc. | One-step target detection assay |
| JP5188789B2 (ja) * | 2007-11-29 | 2013-04-24 | 株式会社日立製作所 | 核酸の定量方法 |
| WO2009098998A1 (ja) | 2008-02-05 | 2009-08-13 | Olympus Corporation | 核酸検出方法及び核酸検出用キット |
| CN102098909B (zh) | 2008-04-24 | 2014-12-31 | 孟山都技术有限公司 | 鉴定大豆中亚洲大豆锈病抗性数量性状基因座的方法和其组合物 |
| EP2113574A1 (en) | 2008-04-28 | 2009-11-04 | Biotype AG | Substances and methods for a DNA based profiling assay |
| EP2644707B1 (en) | 2008-04-30 | 2015-06-03 | Integrated Dna Technologies, Inc. | RNase-H-based assays utilizing modified RNA monomers |
| US8911948B2 (en) * | 2008-04-30 | 2014-12-16 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| CN102076850B (zh) | 2008-07-02 | 2014-05-07 | 爱科来株式会社 | 靶核酸序列的扩增方法、使用该方法的突变检测方法、以及用于该方法的试剂 |
| JP5590781B2 (ja) | 2008-07-10 | 2014-09-17 | オリンパス株式会社 | 標的核酸比率推定方法 |
| WO2010046067A1 (en) * | 2008-10-20 | 2010-04-29 | Roche Diagnostics Gmbh | Improved allele-specific amplification |
| EP2186907A1 (en) | 2008-11-11 | 2010-05-19 | Deutsches Primatenzentrum GmbH | X-chromosomal variation as a diagnostic and therapeutic marker for the progression to AIDS |
| EP3301446B1 (en) | 2009-02-11 | 2020-04-15 | Caris MPI, Inc. | Molecular profiling of tumors |
| CA2751758A1 (en) | 2009-02-11 | 2010-08-19 | Orion Genomics Llc | Combinations of polymorphisms for determining allele-specific expression of igf2 |
| JP5457222B2 (ja) * | 2009-02-25 | 2014-04-02 | エフ．ホフマン−ラ ロシュ アーゲー | 小型化ハイスループット核酸分析 |
| US9347092B2 (en) * | 2009-02-25 | 2016-05-24 | Roche Molecular System, Inc. | Solid support for high-throughput nucleic acid analysis |
| EP2408796B1 (en) | 2009-03-16 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III |
| ES2932874T3 (es) | 2009-03-25 | 2023-01-27 | Genentech Inc | Anticuerpos anti-FGFR3 y métodos que utilizan los mismos |
| WO2010112033A2 (en) | 2009-03-31 | 2010-10-07 | Østjysk Innovation A/S | Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x |
| US20100299773A1 (en) * | 2009-05-20 | 2010-11-25 | Monsanto Technology Llc | Methods and compositions for selecting an improved plant |
| US9587270B2 (en) * | 2009-06-29 | 2017-03-07 | Luminex Corporation | Chimeric primers with hairpin conformations and methods of using same |
| KR101953075B1 (ko) | 2009-10-07 | 2019-02-27 | 제넨테크, 인크. | 루푸스의 치료, 진단 및 모니터링 방법 |
| CA2779223A1 (en) | 2009-10-27 | 2011-05-12 | Caris Mpi, Inc. | Molecular profiling for personalized medicine |
| AU2010315399B2 (en) | 2009-10-27 | 2016-01-28 | Swift Biosciences, Inc. | Bimolecular primers |
| US8614071B2 (en) | 2009-12-11 | 2013-12-24 | Roche Molecular Systems, Inc. | Preferential amplification of mRNA over DNA using chemically modified primers |
| US9238832B2 (en) | 2009-12-11 | 2016-01-19 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids |
| US9284603B2 (en) | 2010-01-21 | 2016-03-15 | Arkray, Inc. | Target sequence amplification method, polymorphism detection method, and reagents for use in the methods |
| WO2011128096A1 (en) | 2010-04-16 | 2011-10-20 | Roche Diagnostics Gmbh | Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
| EP2383348B1 (en) | 2010-04-30 | 2015-03-04 | ARKRAY, Inc. | Method for adjusting amplification efficiency of target polynucleotide |
| US9340833B2 (en) | 2010-04-30 | 2016-05-17 | Arkray, Inc. | Method for adjusting amplification efficiency of target polynucleotide |
| GB201008125D0 (en) | 2010-05-14 | 2010-06-30 | Biofortuna Ltd | Tissue typing assays and kits |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| WO2012071096A2 (en) | 2010-09-03 | 2012-05-31 | The Johns Hopkins University | Arid1a and ppp2r1a mutations in cancer |
| WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
| AU2012206487A1 (en) | 2011-01-14 | 2013-07-18 | Genefirst Limited | Methods, compositions, and kits for determining the presence/absence of a variant nucleic acid sequence |
| GB201101200D0 (en) | 2011-01-24 | 2011-03-09 | King S College | Method |
| WO2012135053A2 (en) | 2011-03-25 | 2012-10-04 | Integrated Dna Technologies, Inc. | Rnase h-based assays utilizing modified rna monomers |
| US20140031259A1 (en) | 2011-04-01 | 2014-01-30 | Genentech, Inc. | Biomarkers for predicting sensitivity to cancer treatments |
| US10172305B2 (en) | 2011-04-29 | 2019-01-08 | Monsanto Technology Llc | Diagnostic molecular markers for seed lot purity traits in soybeans |
| ES2731638T3 (es) | 2011-05-02 | 2019-11-18 | Univ Nebraska | Plantas con rasgos útiles y métodos relacionados |
| CA2845386A1 (en) | 2011-08-31 | 2013-03-07 | F. Hoffmann-La Roche Ag | Method for predicting risk of hypertension associated with anti-angiogenesis therapy |
| CN104024431A (zh) | 2011-08-31 | 2014-09-03 | 霍夫曼-拉罗奇有限公司 | 对血管发生抑制剂的响应 |
| HUE044521T2 (hu) | 2011-08-31 | 2019-10-28 | Seminis Vegetable Seeds Inc | Görögdinnye szilárdságával kapcsolatos eljárások és kompozíciók |
| SG11201400724SA (en) | 2011-09-19 | 2014-04-28 | Genentech Inc | Combination treatments comprising c-met antagonists and b-raf antagonists |
| BR112014008862A2 (pt) | 2011-10-14 | 2018-08-07 | Genentech Inc | anticorpo isolado que se liga à htra1, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, métodos e usos |
| AR088827A1 (es) | 2011-11-10 | 2014-07-10 | Genentech Inc | Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer |
| JP2014533956A (ja) | 2011-11-23 | 2014-12-18 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 血管新生阻害剤に対する応答性 |
| RU2019103083A (ru) | 2011-11-30 | 2019-03-22 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
| CN104114714A (zh) | 2011-12-14 | 2014-10-22 | 阿斯利康(瑞典)有限公司 | Gabr-a2诊断 |
| EP2607495A1 (en) | 2011-12-23 | 2013-06-26 | Genomica S.A.U. | Method for detection of KRAS mutations |
| US10633707B2 (en) | 2012-04-10 | 2020-04-28 | Vib Vzw | Markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the DNA base excision repair pathway |
| US10294529B2 (en) | 2012-04-10 | 2019-05-21 | Life Sciences Research Partners Vzw | Microsatellite instability markers in detection of cancer |
| CA3209140A1 (en) | 2012-04-19 | 2013-10-24 | The Medical College Of Wisconsin, Inc. | Highly sensitive surveillance using detection of cell free dna |
| US10077474B2 (en) | 2012-05-29 | 2018-09-18 | Abbott Molecular, Inc. | Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits |
| EP2711432A1 (en) | 2012-09-21 | 2014-03-26 | Genomica S.A.U. | Method for detection of BRAF and PI3K mutations |
| US10314253B2 (en) | 2012-12-04 | 2019-06-11 | Seminis Vegetable Seeds, Inc. | Methods and compositions for watermelon sex expression |
| JP6669500B2 (ja) | 2013-02-25 | 2020-03-18 | ジェネンテック， インコーポレイテッド | 薬物耐性ａｋｔ変異体を検出し治療するための方法及び組成物 |
| WO2014149356A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Molecular Inc. | Detection of bisulfite converted nucleotide sequences |
| US10294489B2 (en) | 2013-03-15 | 2019-05-21 | Board Of Trustees Of Southern Illinois University | Soybean resistant to cyst nematodes |
| CA2902167A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Molecular Inc. | Method for amplification and assay of rna fusion gene variants, method of distinguishing same and related primers, probes, and kits |
| EP2977464A4 (en) | 2013-03-19 | 2016-10-19 | Toppan Printing Co Ltd | PROCEDURE FOR PREDICTING SENSITIVITY TO EGFR HEMMER |
| US10059999B2 (en) | 2013-06-10 | 2018-08-28 | Monsanto Technology Llc | Molecular markers associated with soybean tolerance to low iron growth conditions |
| US10767188B2 (en) | 2013-09-25 | 2020-09-08 | Nutech Ventures | Methods and compositions for obtaining useful plant traits |
| JP2015096049A (ja) | 2013-11-15 | 2015-05-21 | 凸版印刷株式会社 | Ｖｅｇｆ阻害剤長期奏功性予測方法 |
| NZ735461A (en) | 2013-11-27 | 2020-05-29 | Seminis Vegetable Seeds Inc | Disease resistance loci in onion |
| UA122122C2 (uk) | 2014-02-21 | 2020-09-25 | Сінгента Партісіпейшнс Аг | Спосіб виявлення рослини маїсу, що має підвищену чоловічу фертильність |
| NZ630710A (en) | 2014-02-27 | 2016-03-31 | Seminis Vegetable Seeds Inc | Compositions and methods for peronospora resistance in spinach |
| KR20160138494A (ko) | 2014-03-31 | 2016-12-05 | 데비오팜 인터네셔날 에스 에이 | Fgfr 융합물 |
| TW201620526A (zh) * | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法 |
| US10316369B2 (en) | 2014-06-27 | 2019-06-11 | Seminis Vegetable Seeds, Inc. | Methods and assays for male sterile watermelon |
| CN113016623A (zh) | 2014-09-26 | 2021-06-25 | 谱赛科美国股份有限公司 | 用于甜菊的单核苷酸多态性(snp)标志物 |
| EP3005862A1 (en) | 2014-10-10 | 2016-04-13 | Seminis Vegetable Seeds, Inc. | Melon plants with improved disease tolerance |
| US10208120B2 (en) | 2014-11-05 | 2019-02-19 | Genentech, Inc. | Anti-FGFR2/3 antibodies and methods using same |
| US20160168640A1 (en) | 2014-11-10 | 2016-06-16 | Genentech, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
| US9909169B2 (en) | 2014-12-17 | 2018-03-06 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids using blocking oligonucleotides for wild type suppression |
| HUE053541T2 (hu) | 2015-04-28 | 2021-07-28 | Monsanto Technology Llc | Eljárások és készítmények brachitikus kukoricanövények elõállítására |
| EP3288369A4 (en) | 2015-04-30 | 2018-09-12 | Monsanto Technology LLC | Methods for producing canola plants with clubroot resistance and compositions thereof |
| WO2016183106A1 (en) | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
| CR20180164A (es) | 2015-08-18 | 2018-09-04 | Monsanto Technology Llc | Métodos para producir plantas de algodón con tolerancia mejorada a la sequía y composiciones de estas |
| US10448595B2 (en) | 2015-09-03 | 2019-10-22 | Seminis Vegetable Seeds, Inc. | Downy mildew resistant lettuce plants |
| WO2017044744A2 (en) | 2015-09-10 | 2017-03-16 | Monsanto Technology Llc | Methods for producing corn plants with downy mildew resistance and compositions thereof |
| EP3368578B1 (en) | 2015-10-30 | 2021-03-17 | H. Hoffnabb-La Roche Ag | Anti-htra1 antibodies and methods of use thereof |
| BR112018012039A2 (pt) | 2015-12-18 | 2018-12-04 | Monsanto Technology Llc | métodos para produção de plantas de milho com resistência à helmintosporiose e composições dos mesmos |
| WO2018031874A1 (en) | 2016-08-11 | 2018-02-15 | Monsanto Technology Llc | Methods and compositions for producing corn plants with resistance to late wilt |
| CA3033788A1 (en) * | 2016-08-17 | 2018-02-22 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| AU2017232187B2 (en) | 2016-09-30 | 2023-11-09 | Seminis Vegetable Seeds, Inc. | Xanthomonas resistant brassica oleracea plants |
| CN110177874A (zh) * | 2016-11-02 | 2019-08-27 | 威斯康星州立大学医学院 | 用于使用错配扩增和统计方法来评估风险的方法 |
| US11031099B2 (en) | 2016-11-09 | 2021-06-08 | Roche Molecular Systems, Inc. | Detection of sequence variants |
| WO2018118808A1 (en) | 2016-12-19 | 2018-06-28 | The Broad Institute, Inc. | Methods of treating autism spectrum disorders |
| WO2018170436A1 (en) | 2017-03-16 | 2018-09-20 | Jacobs Farm Del Cabo | Basil with high tolerance to downy mildew |
| TW201902509A (zh) | 2017-04-24 | 2019-01-16 | 美商建南德克公司 | Erbb2/her2突變 |
| CN110914458A (zh) | 2017-05-17 | 2020-03-24 | 麦克罗比奥私人有限公司 | 生物标志物及其用途 |
| EP3642353A4 (en) | 2017-06-20 | 2021-02-24 | The Medical College of Wisconsin, Inc. | ASSESSMENT OF THE RISK OF COMPLICATION OF A TRANSPLANT WITH TOTAL ACELLULAR DNA |
| WO2019013451A1 (ko) | 2017-07-12 | 2019-01-17 | 주식회사 진캐스트 | 유전자 변이 특이성이 증가된 dna 중합효소 및 이의 활성 증가용 pcr 버퍼 조성물 |
| US11648551B2 (en) | 2017-12-12 | 2023-05-16 | Essenlix Corporation | Sample manipulation and assay with rapid temperature change |
| CA3088557C (en) | 2018-02-09 | 2024-02-27 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| US11268102B2 (en) | 2018-05-16 | 2022-03-08 | University Of Florida Research Foundation, Incorporated | Compositions and methods for identifying and selecting brachytic locus in solanaceae |
| MX2021006234A (es) | 2018-11-30 | 2021-09-10 | Caris Mpi Inc | Perfilado molecular de proxima generacion. |
| AU2020208190B2 (en) | 2019-01-15 | 2022-07-28 | Seminis Vegetable Seeds, Inc. | Green bean plants with improved disease resistance |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| CN114341187A (zh) | 2019-07-12 | 2022-04-12 | 中外制药株式会社 | 抗突变型fgfr3抗体及其用途 |
| SG10202008262UA (en) | 2019-09-26 | 2021-04-29 | Seminis Vegetable Seeds Inc | Lettuce plants having resistance to nasonovia ribisnigri biotype nr:1 |
| EP4069865A4 (en) | 2019-12-02 | 2023-12-20 | Caris MPI, Inc. | PLATINUM RESISTANCE TEST FOR PAN CANCER |
| JP2023517078A (ja) | 2020-03-11 | 2023-04-21 | シージェン インコーポレイテッド | ツカチニブを用いてｈｅｒ２突然変異を有するがんを処置する方法 |
| WO2021180858A1 (en) | 2020-03-13 | 2021-09-16 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
| AU2021204717A1 (en) | 2020-07-15 | 2022-02-03 | Seminis Vegetable Seeds, Inc. | Green Bean Plants with Improved Disease Resistance |
| CA3197165A1 (en) | 2020-09-28 | 2022-03-31 | Seagen Inc. | Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody |
| JP2023549581A (ja) | 2020-11-17 | 2023-11-27 | シージェン インコーポレイテッド | ツカチニブ及び抗ｐｄ－１／抗ｐｄ－ｌ１抗体の組み合わせによりがんを治療する方法 |
| US20230193310A1 (en) | 2021-12-10 | 2023-06-22 | Seminis Vegetabe Seeds, Inc. | Lettuce plants having resistance to downy mildew |
| WO2023250288A2 (en) | 2022-06-21 | 2023-12-28 | Seminis Vegetable Seeds, Inc. | Novel qtls conferring resistance to cucumber mosaic virus |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311018D0 (en) * | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US4851331A (en) * | 1986-05-16 | 1989-07-25 | Allied Corporation | Method and kit for polynucleotide assay including primer-dependant DNA polymerase |
| GB8612087D0 (en) * | 1986-05-19 | 1986-06-25 | Ici Plc | Hybridisation probes |
| GB8709652D0 (en) * | 1987-04-23 | 1987-05-28 | Williamson R | Diagnosis of cystic fibrosis |
| US4994368A (en) * | 1987-07-23 | 1991-02-19 | Syntex (U.S.A.) Inc. | Amplification method for polynucleotide assays |
| JP2634208B2 (ja) * | 1987-11-13 | 1997-07-23 | パイオニア・ハイ―ブレツド・インターナシヨナル・インコーポレイテツド | 制限断片長多型性分析方法及びその装置 |
| AU613989B2 (en) * | 1987-11-24 | 1991-08-15 | Gen-Probe Incorporated | Means and method for enhancing nucleic acid hybridization |
| AU2735988A (en) * | 1987-12-21 | 1989-07-13 | Amoco Corporation | Target and background capture methods with amplification for affinity assays |
| US4999290A (en) * | 1988-03-31 | 1991-03-12 | The Board Of Regents, The University Of Texas System | Detection of genomic abnormalities with unique aberrant gene transcripts |
| AU3694689A (en) * | 1988-04-28 | 1989-11-24 | Mark H. Skolnick | Amplified sequence polymorphisms (asps) |
| AU629845B2 (en) * | 1988-08-30 | 1992-10-15 | Abbott Laboratories | Detection and amplification of target nucleic acid sequences |
| CA1339731C (en) * | 1988-10-12 | 1998-03-17 | Charles T. Caskey | Multiplex genomic dna amplification for deletion detection |
| CA2011818A1 (en) * | 1989-03-17 | 1990-09-17 | Fred T. Oakes | Methods for purification, amplification and detection of a nucleic acid |
| AU5640090A (en) * | 1989-03-21 | 1990-11-05 | Collaborative Research Inc. | A dna diagnostic test using an exonuclease activity |
| CA2013317A1 (en) * | 1989-04-17 | 1990-10-17 | Fred T. Oakes | Diagnostic kit, primer composition and their use for replication or detection of nucleic acids |
| US5137806A (en) * | 1989-12-11 | 1992-08-11 | Board Of Regents, The University Of Texas System | Methods and compositions for the detection of sequences in selected DNA molecules |
| US6004744A (en) * | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
-
1989
- 1989-03-07 IE IE73989A patent/IE61148B1/en not_active IP Right Cessation
- 1989-03-08 HU HU891126A patent/HUT52565A/hu unknown
- 1989-03-08 NZ NZ228266A patent/NZ228266A/en unknown
- 1989-03-08 IL IL8954589A patent/IL89545A/en unknown
- 1989-03-09 YU YU49789A patent/YU49789A/sh unknown
- 1989-03-09 DE DE8989302331T patent/DE68901285D1/de not_active Expired - Lifetime
- 1989-03-09 MY MYPI89000284A patent/MY104957A/en unknown
- 1989-03-09 AT AT89302331T patent/ATE75262T1/de not_active IP Right Cessation
- 1989-03-09 ES ES89302331T patent/ES2039294T5/es not_active Expired - Lifetime
- 1989-03-09 FI FI891126A patent/FI891126A/fi not_active Application Discontinuation
- 1989-03-09 CA CA000593183A patent/CA1323592C/en not_active Expired - Lifetime
- 1989-03-09 TN TNTNSN89026A patent/TNSN89026A1/fr unknown
- 1989-03-09 NO NO891012A patent/NO174825B/no not_active IP Right Cessation
- 1989-03-09 EP EP89302331A patent/EP0332435B2/en not_active Expired - Lifetime
- 1989-03-09 CN CN89102694A patent/CN1034673C/zh not_active Expired - Lifetime
- 1989-03-10 BR BR898901136A patent/BR8901136A/pt not_active Application Discontinuation
- 1989-03-10 ZW ZW33/89A patent/ZW3388A1/xx unknown
- 1989-03-10 DK DK198901180A patent/DK175527B1/da not_active IP Right Cessation
- 1989-03-10 JP JP1059492A patent/JP2853864B2/ja not_active Expired - Lifetime
- 1989-03-10 KR KR1019890003001A patent/KR970003151B1/ko not_active IP Right Cessation
- 1989-03-10 PL PL27817689A patent/PL162338B1/pl unknown
- 1989-03-10 PT PT89980A patent/PT89980B/pt not_active IP Right Cessation
- 1989-03-10 AU AU31246/89A patent/AU614584B2/en not_active Expired
-
1992
- 1992-04-23 GR GR910401845T patent/GR3004442T3/el unknown
-
1995
- 1995-02-17 US US08/390,939 patent/US5595890A/en not_active Expired - Lifetime
-
1999
- 1999-10-14 GR GR990402594T patent/GR3031532T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO174825B (no) | Fremgangsmåte ved påvisning av nukleotidsekvenser, nukleotidsekvens for bruk i denne og diagnostisk sett | |
| DK175469B1 (da) | Fremgangsmåde til multiplikation og påvisning af nukleinsyresekvenser | |
| JP2726659B2 (ja) | 核酸中に存在する特定のヌクレオチド配列の検出方法及びそのためのキット | |
| US6696277B1 (en) | Arbitrarily primed polymerase chain reaction method for fingerprinting genomes | |
| JP5386357B2 (ja) | 核酸サイズ検出法 | |
| US5496699A (en) | Detection of allele - specific mutagens | |
| US6200747B1 (en) | Method and kits for detection of fragile X specific, GC-rich DNA sequences | |
| JP5637850B2 (ja) | 標的核酸配列の増幅方法、それを用いた変異の検出方法、および、それに用いる試薬 | |
| US20040166506A1 (en) | Methods and compositions for genotyping | |
| JP5917144B2 (ja) | 疾患関連遺伝子の多型検出用プローブおよびその用途 | |
| CN106591442B (zh) | 用于y染色体微缺失检测的引物组合及试剂盒 | |
| JP2002510962A (ja) | 男性不妊ｙ欠失検出器具 | |
| US9284603B2 (en) | Target sequence amplification method, polymorphism detection method, and reagents for use in the methods | |
| JPH11507222A (ja) | マルチプレックスプライマー結合による男性不妊ｙ染色体欠失検出 | |
| JPWO2011077990A1 (ja) | ｃ−ｋｉｔ遺伝子の多型検出用プローブおよびその用途 | |
| RU2099426C1 (ru) | Способ определения последовательности нуклеотидов | |
| JP5635496B2 (ja) | Ｅｇｆｒ遺伝子多型検出用プローブおよびその用途 | |
| JP5568935B2 (ja) | 標的塩基配列の識別方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |